Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 54,948 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis
Interventions: milatuzumab, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: West Hollywood, California

Conditions: Solid Tumors
Interventions: ONT-10; Biological
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Aurora, Colorado • Dallas, Texas • Tacoma, Washington

Conditions: Periodontal Diseases
Interventions: Methylcellulose, Simvastatin-Methylcellulose; Other · Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions: Azacitidine, Cytarabine, Decitabine, Laboratory Biomarker Analysis, Midostaurin, Nivolumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 506
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 337 more

Conditions: Mammoplasty, Postoperative Pain
Interventions: Instillation - EXPAREL, Infiltration - EXPAREL; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Long Haul COVID, Long-Haul COVID-19
Interventions: Endourage Targeted Wellness Formula C™, a full hemp flower extract; Combination Product
Lead sponsor: Endourage, LLC; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Facial Paralysis
Interventions: Mindfulness Meditation Phone Application; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Lutherville-Timonium, Maryland

Conditions: Lumbar Spinal Stenosis
Interventions: Stabilimax NZ® Dynamic Spine Stabilization System; Device
Lead sponsor: Applied Spine Technologies; Industry
Eligibility: 21 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Oceanside, California + 16 more

Conditions: Gaucher's Disease
Interventions: Lysodase; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: AS1411, Cytarabine; Drug
Lead sponsor: Antisoma Research; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Charleston, South Carolina

Conditions: Venous Thromboembolism
Interventions: Application of VTE Risk Assessment; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
Interventions: Laboratory Biomarker Analysis, Selumetinib Sulfate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Birmingham, Alabama • Bethesda, Maryland

Conditions: Chronic Kidney Disease, End-Stage Renal Disease
Interventions: Digital Education; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Uveitis
Interventions: AIN457, Placebo; Biological
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Medication Adherence
Interventions: Nudges Intervention; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Epithelial Tumors, Malignant
Interventions: MEHD7945A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 3
States / cities: Aurora, Colorado • Boston, Massachusetts • Houston, Texas

Conditions: Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: psychosocial assessment and care; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania + 2 more

Conditions: Pain, Peripheral Neuropathy
Interventions: scrambler therapy, questionnaire administration, management of therapy complications; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Intubated ICU Patients
Interventions: shortened fast; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: MDS, Leukemias, Lymphomas
Interventions: Busulfan, Cyclophosphamide, Total body irradiation; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), T2DM (Type 2 Diabetes Mellitus), T2D, T2DM, Remote Patient Monitoring, Artificial Intelegence
Interventions: Fitbit and AI Chatbot, Routine Care; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Mipomersen sodium, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 62
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more

Conditions: Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound
Interventions: Negative Pressure Wound Therapy System; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 4
States / cities: Miami Lakes, Florida • Chicago, Illinois • Lake Success, New York + 1 more

Search by objective public record fields.

Phase Ib Study of SC Milatuzumab in SLE

Phase 1 Study of ONT-10 in Patients With Solid Tumors

Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Study of EXPAREL in Patients Undergoing Breast Augmentation

Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops

Effects of Mindfulness Meditation on Facial Paralysis Patients

Dynamic Stabilization for Lumbar Spinal Stenosis With Stabilimax NZ® Dynamic Spine Stabilization System

PEG-Glucocerebrosidase for the Treatment of Gaucher Disease

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Health Outcomes Patient Education

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

Improvement in Medication Adherence Through the Implementation of Personalized Nudges: the ENCOURAGE Trial

A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors

Study of Decision Making in Patients Participating in Phase I Clinical Trials

Scrambler Therapy in Treating Pain and Peripheral Neuropathy in Patients Previously Treated With Chemotherapy

Shortened Preoperative Fasts in ICU

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System